Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / Rahman 9-marker MALDI MS panel for Lung Cancer

Rahman 9-marker MALDI MS panel for Lung Cancer

Basics

Attributes

QA State: Curated
Short Name:

This panel was derived from the proteomic analysis of bronchial lesions that could predict the diagnosis of lung cancer. Nine matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) mass to charge ratio features were selected to build a prediction model diagnostic of lung cancer. One signature was not able to be associated with a particular protein. The remaining eight signatures are derived from: Thymosin beta-4 (TMSB4X), Macrophage migration inhibitory factor (MIF), Des-ubiquitin (Ubiquitin-Gly-Gly), Ubiquitin, Acyl-coA binding protein (ACBP, also known as DBI), Cystatin A (CSTA), and Cytochrome c.

Panel Details

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Determining the probability of having lung cancer based on a novel proteomic signature of bronchial lesions may have important clinical implications. This signature may facilitate the diagnosis of lung cancer and the monitoring of high-risk individuals for lung cancer in surveillance and chemoprevention trials.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Organs

No associated resources found.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.

Announcement